CD19 and neoplasm: ,58,59,60 To closely simulate the clinical CAR-T cell therapeutic mechanisms, we engineered B16 tumor cells to express the clinically relevant human CD19 antigen (hCD19-B16), and then hCD19-B16 cells were utilized to establish solid tumor models with the ability to generate functional tumor ECM (Figure S11A).